HOME >> BIOLOGY >> NEWS
Tiny Molecular Channels Key To Protecting Heart During Attack

Hopkins Finding Could Lead To Development Of Better Cardioprotective Drugs

Researchers at Johns Hopkins have come one step closer to understanding the chain of events that protects the heart against injury during a heart attack, paving the way for the development of a new class of drugs to treat people at risk.

The team has found that tiny, energy-dependent channels within mitochondria -- the sacs of enzymes that act as powerhouses of cells -- may play a significant role during "preconditioning," a process in which brief coronary blood flow stoppages that precede a major heart event protect the heart against severe damage. Mitochondria convert carbohydrate energy into ATP (adenosine triphosphate), the type of energy needed for such functions as muscle contraction.

Using rabbit heart cells, the researchers found that the blood pressure medicine diazoxide opened up channels in the cell membranes that let potassium flow into the cells. The drug opened the potassium channels in the mitochondria but had no effect on other channels. The team also found that when oxygen supply to the heart cells was stopped, as happens during a heart attack, diazoxide halved the rate of cell death.

Results of the study, supported by the National Institutes of Health, were published in the June 30 issue of Circulation: Journal of the American Heart Association. "During periods of ischemia, or lack of blood flow, cells lose energy and die," says Eduardo Marban, M.D., Ph.D., director of molecular and cellular cardiology at Hopkins and senior author of the study. "If we could keep the energy levels high during heart failure or a heart attack, we could buy time. While we're still not sure how opening these mitochondrial channels might protect heart cells from dying, we know that their role is crucial. This will help in developing a more effective class of cardioprotective drugs.

"There is goo
'"/>

Contact: Karen Infeld
kinfeld@jhmi.edu
(410)955-1534
Johns Hopkins Medical Institutions
30-Jun-1998


Page: 1 2

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular marker predicts success of breast cancer treatment
10. Molecular image of genotoxin reveals how bacteria damage human DNA
11. Molecular mechanism found that may improve ability of stem cells to fight disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: